Compare BZ & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZ | BLCO |
|---|---|---|
| Founded | 2013 | 1853 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Ophthalmic Goods |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.4B |
| IPO Year | 2021 | 2022 |
| Metric | BZ | BLCO |
|---|---|---|
| Price | $13.70 | $14.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $23.00 | $18.45 |
| AVG Volume (30 Days) | ★ 3.4M | 408.0K |
| Earning Date | 05-21-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | $15.92 | $8.65 |
| Revenue Next Year | $12.78 | $5.59 |
| P/E Ratio | $22.61 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $12.85 | $11.63 |
| 52 Week High | $25.26 | $18.92 |
| Indicator | BZ | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 37.00 |
| Support Level | $13.02 | $14.61 |
| Resistance Level | $14.77 | $15.67 |
| Average True Range (ATR) | 0.59 | 0.39 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 39.40 | 19.73 |
Kanzhun's Boss Zhipin job platform connects job seekers and employers. Boss Zhipin is China's largest online recruitment platform based on monthly active users, or MAU, and was established in 2014. Kanzhun earns revenue by providing services to enterprise customers primarily through its mobile app, which promotes engagement between recruiters and workers and operates on a recommendation basis powered by artificial intelligence. The platform specializes in transportation, logistics, construction, and service-based industries. About 85% of the companies looking to hire are small and medium-size enterprises. Its main competitors are 58.com, 51job, and Zhilian Zhaopin. Tencent has a 9.2% stake in Kanzhun.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.